yeztugo hiv - Search News

News

HIV, CVS Health and Yeztugo

For now, CVS declines to cover Gilead's long-acting HIV PrEP treatment Yeztugo

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV prevention breakthrough, at least for now. | CVS Health, the parent of PBM juggernaut CVS Caremark,

· 1d · on MSN

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.

· 16h

GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo

From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

STAT1d

Pharmalittle: We’re reading about Gilead’s HIV drug, FDA speeding review of a rare disease drug, and more

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

Nasdaq1mon

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo ... - Nasdaq

HIV- 1 resistance substitutions may emerge in individuals with undiagnosed HIV-1 infection taking only Yeztugo, because Yeztugo alone is not a complete regimen for HIV-1 treatment.

Seeking Alpha1mon

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for ...

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025 Jul. 14, 2025 9:30 AM ET Gilead Sciences, Inc. (GILD) ...

4don MSN

New HIV prevention injection could be a ‘Game Changer,’ advocates say

Advocates for HIV prevention are calling a newly approved injectable medication a major step in eliminating the spread of the ...

GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results